Real-World Assessment of Switching from a Dipeptidyl Peptidase-4 Inhibitor to Exenatide Once-Weekly in Patients with Type 2 Diabetes

被引：0
|
作者：
Gorgojo-Martinez, Juan J.
Gargallo-Fernandez, Manuel A.
Brito-Sanfiel, Miguel A.
Lisbona-Catalan, Arturo
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1118-P
引用
收藏
页码：A297 / A297
页数：1
相关论文
共 50 条
  • [41] Real-world use of once-weekly semaglutide in type 2 diabetes: Results from the SURE UK study
    Holmes, P.
    Catarig, A. M.
    Clark, A.
    Erhan, U.
    Sathyapalan, T.
    DIABETIC MEDICINE, 2021, 38
  • [42] Dipeptidyl Peptidase-4 Inhibitor Use and Risk of Acute Pancreatitis in Patients with Type 2 Diabetes
    Seong, J.
    Choi, N.
    Kim, J.
    Lee, J.
    Kim, Y.
    Park, B.
    DRUG SAFETY, 2013, 36 (09) : 856 - 856
  • [43] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Deacon, Carolyn F.
    Holst, Jens J.
    ADVANCES IN THERAPY, 2009, 26 (05) : 488 - 499
  • [44] Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study
    Napoli, Raffaele
    Berra, Cesare
    Catarig, Andrei-Mircea
    Di Loreto, Chiara
    Donatiello, Emily
    Berentzen, Tina Landsvig
    Pitocco, Dario
    Giorgino, Francesco
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1658 - 1667
  • [45] Linagliptin: The Newest Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
    Aletti, Rachael
    Cheng-Lai, Angela
    CARDIOLOGY IN REVIEW, 2012, 20 (01) : 45 - 51
  • [46] Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
    Neumiller, Joshua J.
    Campbell, R. Keith
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (18) : 1515 - 1525
  • [47] Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus
    Forst, Thomas
    Pfuetzner, Andreas
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (01) : 21 - 35
  • [48] Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study)
    Ishii, Hitoshi
    Kamei, Nozomu
    Shimono, Dai
    Niiya, Tetsuji
    Tosaki, Takahiro
    Kitazawa, Toru
    Suzuki, Daisuke
    Wakasa, Yutaka
    Seino, Hiroaki
    Oishi, Mariko
    Ohashi, Hiroshi
    Higami, Kenshi
    Akai, Hiroaki
    DIABETES THERAPY, 2023, 14 (10) : 1639 - 1658
  • [49] Alogliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
    Jarvis, Courtney I.
    Cabrera, Adriana
    Charron, Derek
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1532 - 1539
  • [50] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Carolyn F. Deacon
    Jens J. Holst
    Advances in Therapy, 2009, 26 : 488 - 499
12345